Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Colgan

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|May 4, 2012
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|September 25, 2014
Survival in patients with limited-stage peripheral T-cell lymphomasRobert Briski, Andrew L Feldman, Nathaniel G Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology ResourceBrian K Link, Matthew J Maurer, Grzegorz S Nowakowski, et al.
Blood|February 4, 2016
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionSaad Sirop Kenderian, Thomas M Habermann, William R Macon, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaNadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|May 4, 2012
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|September 25, 2014
Survival in patients with limited-stage peripheral T-cell lymphomasRobert Briski, Andrew L Feldman, Nathaniel G Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology ResourceBrian K Link, Matthew J Maurer, Grzegorz S Nowakowski, et al.
Blood|February 4, 2016
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionSaad Sirop Kenderian, Thomas M Habermann, William R Macon, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaNadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.
American Journal of Hematology|September 18, 2014
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaThomas E Witzig, Matthew J Maurer, Thomas M Habermann, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Pageof 4